Drug Trial Radar · NCT07867262
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Dec 15, 2026
Primary completion
Aug 15, 2030
Study completion Aug 15, 2030
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the safety, pharmacokinetics, and preliminary activity of GDC-4198 when given in combination with endocrine therapy (ET) (letrozole, fulvestrant, or giredestrant) as first-line treatment to participants with locally advanced or metastatic Hormone receptor (HR)-positive, Human epidermal growth factor receptor-2 (HER2)-negative breast cancer
Conditions
- Advanced or Metastatic Breast Cancer
Interventions
GDC-4198Drug
Participants will receive GDC-4198 as per the schedule described in the protocol.
FulvestrantDrug
Participants will receive fulvestrant as per the schedule described in the protocol.
LetrozoleDrug
Participants will receive letrozole as per the schedule described in the protocol.
GiredestrantDrug
Participants will receive giredestrant as per the schedule described in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: Approximately 30 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.